Zi Yin, Chao Liu, Yajin Chen, Yu Bai, Changzhen Shang, Rongyan Yin, Dong Yin, Jie Wang – 28 January 2013 – The optimal surgical strategy for treatment of patients with synchronous colorectal liver metastases (SCLRM) remains controversial. We conducted a systematic review and meta‐analysis of all observational studies to define the safety and efficacy of simultaneous versus delayed resection of the colon and liver. A search for all major databases and relevant journals from inception to April 2012 without restriction on languages or regions was performed.

Paul J. Pockros, Donald Jensen, Naoky Tsai, Ryan Taylor, Alnoor Ramji, Curtis Cooper, Rolland Dickson, Alan Tice, Rohit Kulkarni, John M. Vierling, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the JUMP‐C Investigators – 28 January 2013 – Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA‐dependent RNA polymerase, with activity across all HCV genotypes.

Richard J. Aspinall – 28 January 2013

Jaime Bosch – 28 January 2013

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Dale J. Hu, Jian Xing, Rania A. Tohme, Youlian Liao, Henry Pollack, John W. Ward, Scott D. Holmberg – 28 January 2013 – Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009‐2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S.

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Chundamannil E. Eapen, Joshua E. Elias, Ian Mackie, Elwyn Elias – 24 January 2013

Heiner Wedemeyer, Donald Jensen, Robert Herring, Peter Ferenci, Mang‐Ming Ma, Stefan Zeuzem, Maribel Rodriguez‐Torres, Natalie Bzowej, Paul Pockros, John Vierling, David Ipe, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the PROPEL Investigators – 24 January 2013 – Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV).

Thibaut Vausselin, Noémie Calland, Sandrine Belouzard, Véronique Descamps, Florian Douam, François Helle, Catherine François, Dimitri Lavillette, Gilles Duverlie, Ahmed Wahid, Lucie Fénéant, Laurence Cocquerel, Yann Guérardel, Czeslaw Wychowski, Christophe Biot, Jean Dubuisson – 24 January 2013 – Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti‐HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)‐free treatments.